Received Apr 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | UNK | — |
received Bexsero below the age of 10 years; This non-serious case was reported by a other health professional via sales rep and described the occurrence of inappropriate age at vaccine administration in an unspecified number of patients who received Men B NVS (Bexsero) for prophylaxis. On an unknown date, the patient received Bexsero. On an unknown date, an unknown time after receiving Bexsero, the patient experienced inappropriate age at vaccine administration (Verbatim: received Bexsero below the age of 10 years). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-APR-2025 The reporter stated that pediatric patients in large national health system received Bexsero that are below the age of 10 years which led to inappropriate age at vaccine administration. The reporter stated that this was off label use. The Health Care Professional estimated that over 30 patients in the previous year and some had received one dose and others have received more than one dose. As Per Health Care Professional, recommendations appear to be coming from Pediatric Infectious Disease providers or Pediatric Oncology providers.